We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Neurocrine Biosciences Inc | NASDAQ:NBIX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.85 | -1.58% | 115.02 | 113.07 | 117.00 | 116.93 | 113.79 | 116.87 | 1,473,352 | 01:00:00 |
From Feb 2023 to Feb 2025
By Ben Glickman
Neurocrine Biosciences has received breakthrough therapy designation for its treatment for congenital adrenal hyperplasia from the U.S. Food and Drug Administration.
The San Diego-based biotechnology company said Tuesday it was on track to submit a new drug application for crinecerfont in the treatment of congenital adrenal hyperplasia, a genetic disorder, in 2024.
The company announced it was on track to advance two gene therapies into the clinic in 2025, and expects to have more than 20 development candidates by 2027.
Chief Medical Officer Eiry Roberts said the FDA designation for crinecerfont was an acknowledgement of the seriousness of congenital adrenal hyperplasia and the unmet need faced by patients.
Breakthrough therapy designation is given by the FDA to speed up development of treatments for serious conditions that show preliminary evidence of effectiveness.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 05, 2023 16:38 ET (21:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Neurocrine Biosciences Chart |
1 Month Neurocrine Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
